SCHEMBL1194367

SCHEMBL1194367

O=C(O)CC(C(=O)O)N1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.61
POLB P06746 1/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPSR1 Q6W5P4 2/20 0.52
ALDH1A1 P00352 3/20 0.42
GLA P06280 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP8 P22894 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28297076 1.00 HSD17B10 (0.61) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL17706711 0.85 HSD17B10 (0.43) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL8562008 0.85 HSD17B10 (0.43) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL11713448 0.85 HSD17B10 (0.43) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL7096628 0.85 HSD17B10 (0.58) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL22407265 0.83 L3MBTL1 (0.47) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL31532972 0.81 L3MBTL1 (0.41) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL28094720 0.81 HSD17B10 (0.50) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL24550941 0.80 HSD17B10 (0.53) HSD17B10POLBMAPK1L3MBTL1NPSR1
SCHEMBL997678 0.80 HSD17B10 (0.53) HSD17B10POLBMAPK1L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7887835-B2 for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome FUJIFILM CORPORATION (JP) 2011-02-15 US disclosed
US-20080138285-A1 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound FUJIFILM CORPORATION (JP) 2008-06-12 US disclosed
EP-1916255-A2 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound FUJIFILM Corporation (JP) 2008-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080138285-A1 Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound PHOSPHO1, SGMS1, SGMS2 HSD17B10 1097/4885POLB 3865/4885MAPK1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.